KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Account Payables (2016 - 2019)

Historic Change in Account Payables for Alnylam Pharmaceuticals (ALNY) over the last 11 years, with Q3 2019 value amounting to -$30.1 million.

  • Alnylam Pharmaceuticals' Change in Account Payables fell 43118.33% to -$30.1 million in Q3 2019 from the same period last year, while for Sep 2019 it was $12.4 million, marking a year-over-year increase of 622.32%. This contributed to the annual value of $15.5 million for FY2018, which is 41338.33% up from last year.
  • As of Q3 2019, Alnylam Pharmaceuticals' Change in Account Payables stood at -$30.1 million, which was down 43118.33% from $43.5 million recorded in Q2 2019.
  • Alnylam Pharmaceuticals' Change in Account Payables' 5-year high stood at $43.5 million during Q2 2019, with a 5-year trough of -$30.1 million in Q3 2019.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Change in Account Payables value was $328500.0 (recorded in 2015), while the average stood at $552687.5.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Change in Account Payables crashed by 328933.72% in 2017, and later skyrocketed by 637734.49% in 2019.
  • Over the past 5 years, Alnylam Pharmaceuticals' Change in Account Payables (Quarter) stood at $2.6 million in 2015, then crashed by 86.45% to $347000.0 in 2016, then surged by 3453.89% to $12.3 million in 2017, then soared by 30.78% to $16.1 million in 2018, then tumbled by 286.56% to -$30.1 million in 2019.
  • Its last three reported values are -$30.1 million in Q3 2019, $43.5 million for Q2 2019, and -$17.1 million during Q1 2019.